A perspective on the diagnostics, prognostics, and therapeutics of microRNAs of triple-negative breast cancer
- 266 Downloads
Triple-negative breast cancer (TNBC) is the most aggressive and prevalent subtype of breast cancer in women worldwide. Currently, chemotherapy remains the main modality for the treatment at an early stage, as there is no approved targeted therapy for early TNBC. In this review, we investigate the use of microRNAs (miRNAs), which play a key role in the post-transcriptional regulation of genes involved in the key biological processes, namely proliferation, differentiation, angiogenesis, migration, apoptosis, and carcinogenesis. Here, we emphasize the importance of the recent advances related to miRNAs, involving diagnosis, prognosis, and treatment of TNBC. We focus on the development, optimization, and stabilization of miRNA-based drugs; improvement of miRNA delivery; and control of the off-target effects of miRNA therapeutics. We speculate as to which features may present themselves as promising approaches in the treatment of TNBC.
KeywordsTNBC miRNA Cancer biomarkers miRNA-based therapy
- Bmi 1
B lymphoma Mo-MLV insertion region 1 homolog
Cancer stem cells
- HER 2
Human epidermal growth factor receptor 2
Triple-negative breast cancer
Tumor suppressor microRNA
We would like to thank DST-EMR/2016/002694, DST-FIST (SR/FST/LSI-568/2013), and GITAM (Deemed to be University) for providing lab facilities.
RRM and SK contributed in designing of review. AKB, MM, SN participated in drafting and editing the manuscript. All authors have read and approved the final manuscript.
Compliance with ethical standards
Conflict of interest
Rama Rao Malla declares that he has no conflict of interest. Seema Kumari declares that she has no conflict of interest. Murali Mohan Gavara declares that he has no conflict of interest. Anil Kumar Badana Gavara declares that he has no conflict of interest. Shailender Gugalavath declares that he has no conflict of interest. Deepak Kakara Gift Kumar declares that he has no conflict of interest. Prasuja Rokkam declares that she has no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- Ahmad J, Hasnain SE, Siddiqui MA et al (2013) MicroRNA in carcinogenesis & cancer diagnostics: a new paradigm. Indian J Med Res 137:680–694Google Scholar
- Choudhury NR, Alves F de L, de Andrés-Aguayo L et al (2013) Tissue-specific control of brain-enriched miR-7 biogenesis. Genes Dev. https://doi.org/10.1101/gad.199190.112
- Cuk K, Zucknick M, Madhavan D et al (2013) Plasma MicroRNA panel for minimally invasive detection of breast cancer. PLoS One 8. https://doi.org/10.1371/journal.pone.0076729
- De Santi C, Melaiu O, Bonotti A et al (2017) Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism. Sci Rep 7. https://doi.org/10.1038/s41598-017-02694-0
- Guessous F, Zhang Y, Kofman A et al (2010) microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell CycleGoogle Scholar
- Hamam R, Ali AM, Alsaleh KA et al (2016) microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. Sci Rep 6. https://doi.org/10.1038/srep25997
- Herranz M, Ruibal A (2012) Optical imaging in breast cancer diagnosis: the next evolution. J Oncol. https://doi.org/10.1155/2012/863747
- Kumari S, Badana A, Gayatridevi V, et al (2016) Coralyne targets proteases involved in cancer progression: an in silico study. In: SpringerBriefs in applied sciences and Technology pp 19–30Google Scholar
- Kumari S, Badana AK, Mohan GM et al (2017) Synergistic effects of coralyne and paclitaxel on cell migration and proliferation of breast cancer cells lines. Biomed Pharmacother 91. https://doi.org/10.1016/j.biopha.2017.04.027
- Kume K, Iwama H, Deguchi K et al (2017) Serum microRNA expression profiling in patients with multiple system atrophy. Mol Med Rep. https://doi.org/10.3892/mmr.2017.7995
- Lal A, Thomas MP, Altschuler G et al (2011) Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. PLoS Genet. https://doi.org/10.1371/journal.pgen.1002363
- Le Bourgeois T, Strauss L, Aksoylar H-I et al (2018) Targeting T cell metabolism for improvement of cancer immunotherapy. Front Oncol. https://doi.org/10.3389/fonc.2018.00237
- Li H, Bian C, Liao L, Li J, Zhao RC (2011) miR-17-5p promotes human breast cancer cell migration and invasion through suppression of HBP1. Breast Cancer Res Treat 126(3):565–575Google Scholar
- Li P, Dong J, Zhou X, Sun W, Huang H, Chen T, Ye B, Zheng Z, Lu M (2017) Expression patterns of microRNA-329 and its clinical performance in diagnosis and prognosis of breast cancer. OncoTargets and Therapy 10:5711–5718Google Scholar
- Lyng MB, Lænkholm AV, Søkilde R et al (2012) Global microRNA expression profiling of high-risk ER+ breast cancers from patients receiving adjuvant tamoxifen mono-therapy: a DBCG study. PLoS One 7. https://doi.org/10.1371/journal.pone.0036170
- Malissen N, Grob JJ (2018) Metastatic melanoma: recent therapeutic progress and future perspectives. DrugsGoogle Scholar
- Pihong L, Jianda D, Xiang Z, et al (2017) Expression patterns of microRNA-329 and its clinical performance in diagnosis and prognosis of breast cancer. Onco Targets Ther 10:5711–5718Google Scholar
- Pustylnikov S, Costabile F, Beghi S, Facciabene A (2018) Targeting mitochondria in cancer: current concepts and immunotherapy approaches. Transl ResGoogle Scholar
- Qi L, Bart J, Tan LP et al (2009) Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer 9. https://doi.org/10.1186/1471-2407-9-163
- Song SJ, Poliseno L, Song MS et al (2013) XMicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 154. https://doi.org/10.1016/j.cell.2013.06.026
- Xiu B, Zhang W, Huang B et al (2013) Genetic inhibition of vascular endothelial growth factor receptor-1 significantly inhibits the migration and proliferation of leukemia cells and increases their sensitivity to chemotherapy. Oncol Rep 29:2030–2038. https://doi.org/10.3892/or.2013.2348 CrossRefGoogle Scholar